4Filed Aug 6, 8:00 PM ET

Braveheart (BRVE) 10% Owner Forbion Buys 3.6M Shares ($64.8M)

$BRVE · Braveheart Bio, Inc.

Research Summary

AI-generated summary of this SEC filing

Updated

Braveheart (BRVE) 10% Owner Forbion Buys 3.6M Shares ($64.8M)

What Happened

  • Forbion Growth Opportunities Fund III Cooperatief U.A. (a reported 10% owner) completed several transactions on 2026-08-07. It made two open‑market/private purchases: 1,920,000 shares at $18.00 ($34,560,000) and 1,680,000 shares at $18.00 ($30,240,000), totaling 3,600,000 shares for $64,800,000 in cash — a sizeable institutional purchase.
  • The filing also shows multiple "conversion of derivative security (C)" entries recorded at $0.00: acquisitions of 9,132,420 and 7,990,867 shares (non‑cash) and dispositions of 40,000,000 and 35,000,000 shares (also recorded at $0). Footnote F1 explains that, upon the issuer's IPO, Series A Preferred Stock automatically converted into Common Stock on a one‑for‑4.38 basis without cash payment.

Key Details

  • Transaction date: 2026-08-07 for all listed entries.
  • Open‑market purchases: 1,920,000 @ $18.00 ($34,560,000) and 1,680,000 @ $18.00 ($30,240,000); combined cash outlay = $64,800,000.
  • Conversion entries (non‑cash): +9,132,420; +7,990,867 shares acquired; -40,000,000; -35,000,000 shares listed as disposed — all recorded with $0 consideration.
  • Post‑transaction beneficial ownership: not specified in the provided summary — see the full Form 4 for exact holdings after these transactions.
  • Footnotes: F1 describes automatic Series A Preferred → Common conversion (1:4.38). F2/F3 note Forbion Growth III Management B.V. (and a related manager) may be deemed to have voting/dispositive power; reporting persons disclaim beneficial ownership except to the extent of pecuniary interest.
  • Filing timeliness: no late‑filing indication in the provided data.

Context

  • The $64.8M in open‑market purchases is a clear cash investment by a large institutional holder — purchases are often viewed as a stronger signal than sales, though institutions have many reasons to buy.
  • The zero‑price "conversion of derivative security" items are non‑cash corporate events (automatic preferred‑to‑common conversions on IPO per F1), not market purchases or cash sales.
  • This activity is reported for a 10% institutional owner (not an executive); footnotes indicate managerial entities may control voting/dispositive power, and the reporting persons disclaim Section 16 beneficial ownership except for any pecuniary interest.